Optigenomics raises £450k to optimize cell line manufacturing

Improving the performance of mammalian host cell lines is the core focus of Optigenomics Limited, which recently raised an estimated £450k in new capital. The entity utilizes systems biology approaches to enhance productivity and process robustness for biologics, viral vector, and cell therapy production.

The London startup targets CHO and HEK293 systems to diagnose and solve expression problems for biopharma groups, gene therapy developers, and contract development and manufacturing organizations. Its causality engine is designed to assist with difficult-to-express molecules and modalities where conventional approaches plateau.

Incorporated in 2024, the firm conducts research and experimental development activities within the biotechnology sector and currently employs 11 people. This latest injection brings the total secured in 2026 to £750k. It follows a larger funding year in 2025, during which the business obtained £3m. The documentation for this specific transaction was filed in May (with a matching allotment date).